US Hereditary Angioedema Association 2025 National Summit

Jul 10 - Jul 13, 2025

  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study  
    Presenter: Michael E. Manning, M.D. 
    Format: Poster Presentation, #22 
    Date, time: Friday, July 11, 12:30-13:30 ET
  • Title: Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 
    Presenter: Michael E. Manning, M.D. 
    Format: Poster Presentation, #20 
    Date, time: Friday, July 11, 12:30-13:30 ET
  • Title: CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 
    Presenter: H. Henry Li, M.D., Ph.D. 
    Format: Poster Presentation, #5 
    Date, time: Friday, July 11, 12:30-13:30 ET
  • Title: Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 
    Presenter: Marc A. Riedl, M.D., M.S. 
    Format: Poster Presentation, #23 
    Date, time: Friday, July 11, 12:30-13:30 ET
  • Title: Durability of response to a single dose of oral deucrictibant for on-demand treatment of hereditary angioedema attacks 
    Presenter: Joshua S. Jacobs, M.D. 
    Format: Poster Presentation, #9 
    Date, time: Friday, July 11, 12:30-13:30 ET
  • Title: Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis 
    Presenter: Mark D. Scarupa, M.D. 
    Format: Poster Presentation, #7 
    Date, time: Friday, July 11, 12:30-13:30 ET 

Supporting Materials

Long-Term Safety and Efficacy of Oral Deucrictibant for Prophylaxis in Hereditary Angioedema: Data Snapshot Results of the CHAPTER-1 Open-Label Extension Study 464.7 KB
Long-Term Prophylactic Treatment with Oral Deucrictibant Improves Disease Control and Health-Related Quality of Life in Participants with Hereditary Angioedema: CHAPTER-1 Open-Label Extension Study 444.4 KB
CHAPTER-3 Phase 3 Trial Design: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Extended-Release Tablet for Prophylaxis of Hereditary Angioedema Attacks 488.1 KB
Long-Term Safety and Efficacy of Oral Deucrictibant for Treatment of Hereditary Angioedema Attacks: Results of the RAPIDe-2 Extension Study 334.3 KB
Durability of Response to a Single Dose of Oral Deucrictibant for On-Demand Treatment of Hereditary Angioedema Attacks 378.1 KB
Deucrictibant vs. Standard of Care in Hereditary Angioedema: A Propensity Score-Matched Analysis 480.5 KB